Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Short Interest Update

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 45,400 shares, a growth of 168.6% from the October 15th total of 16,900 shares. Based on an average daily volume of 90,000 shares, the short-interest ratio is currently 0.5 days. Approximately 1.7% of the shares of the company are short sold.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Northland Securities restated a “market perform” rating and issued a $2.00 price target on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Brookline Capital Management restated a “hold” rating on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. StockNews.com assumed coverage on shares of Oncternal Therapeutics in a research report on Monday. They issued a “hold” rating on the stock. Northland Capmk lowered shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Finally, HC Wainwright decreased their price target on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $20.00.

Institutional Trading of Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Price Performance

Shares of Oncternal Therapeutics stock traded up $0.03 during trading on Friday, hitting $1.14. 61,780 shares of the company’s stock traded hands, compared to its average volume of 34,770. The firm’s fifty day moving average price is $1.63 and its 200 day moving average price is $5.21. Oncternal Therapeutics has a twelve month low of $1.03 and a twelve month high of $13.14. The company has a market cap of $3.37 million, a PE ratio of -0.09 and a beta of 1.33.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.